Dvorit Samid, PhD
SVP, Medical Affairs
Dr. Samid joined NantKwest in 2015 as its Senior Vice President of Medical Affairs and serves as a key driver for the Cancer MoonShot 2020 program, which aims to accelerate personalized, next-generation immunotherapy for patients with cancer. Dr. Samid brings more than 30 years of oncology drug development experience, from preclinical through several successful product launches to the oncology market. Prior to joining the team, Dr. Samid served as head of medical affairs for several public companies including Synta Pharmaceuticals, ImClone Systems, Allos Therapeutics, Abraxis Oncology and Roche Labs. Prior to this, Dr. Samid served as an associate professor at the University of Virginia’s Cancer Center and as section chief for the National Cancer Institute. She earned a doctorate degree in Cell Biology from Catholic University of America in Washington, D.C. and a Bachelor of Science degree in Microbiology from Hebrew University in Jerusalem, Israel. She has authored more than 80 publications in oncology and holds 19 patents.